Reliance Global Group, Inc. (EZRA) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Reliance Global Group, Inc. (formerly Ethos Media Network) operates as a holding company managing insurance distribution businesses and a new strategic venture platform, EZRA International Group. The company recently changed its ticker symbol to "EZRA" and is currently addressing Nasdaq listing compliance regarding minimum bid price requirements.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $3,826,792 | $4,236,220 |
| Net Loss | $(1,471,167) | $(1,736,882) |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.66) |
| Cash and Restricted Cash | $3,235,363 | $1,811,507 |
| Working Capital | $2,604,000 | $1,875,000 |
| Total Debt (Current + Long-Term) | $4,498,241 | $5,101,266 |
| Adjusted EBITDA (AEBITDA) | $(427,735) | $145,407 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 10% year-over-year, primarily due to the divestiture of three insurance agencies (Fortman Insurance Services, Employee Benefits Solutions, and U.S. Benefits Alliance) in 2025. This was partially offset by approximately 11% organic growth in retained businesses.
- Expense Reductions: Salaries and wages dropped 28% and General & Administrative expenses fell 11%, driven by lower non-cash equity compensation and the elimination of costs associated with divested entities.
- Segment Restructuring: The company established a new "Strategic Ventures" segment in Q1 2026 to track technology and life sciences investments. This segment reported a net loss of approximately $365,000, while the Insurance segment remained profitable with net income of $743,515.
- Capital Raising: The company completed a Series K Public Offering generating gross proceeds of ~$2.0 million and raised additional funds through warrant exercises and ATM sales, significantly improving liquidity compared to the prior year.
Outlook, Risks, and Unusual Items
- Strategic Investments: The company invested ~$500,000 in Enquantum Ltd. (quantum encryption) and formed LifeSci Global Group (LGG) to invest in Innervate Radiopharmaceuticals. These are high-risk, early-stage ventures with significant unfunded commitments.
- Nasdaq Compliance: The company received a deficiency notice for failing to meet the $1.00 minimum bid price requirement. A 1-for-40 reverse stock split was approved on May 7, 2026, to regain compliance by June 10, 2026.
- Digital Assets: The company holds digital assets (ZEC) valued at $52,970, recognizing an unrealized loss of $55,943 for the quarter due to fair value adjustments.
- Related Party Transactions: Significant related party transactions occurred, including settlements of prior guarantees ($130,910 paid) and the formation of LGG, where management holds minority interests.
- Discontinued Transaction: The company discontinued discussions regarding the acquisition of Scentech Medical Ltd. with no termination fees incurred.
Investor Verification Checklist
- Reverse Stock Split Effectiveness: Verify the successful implementation of the 1-for-40 reverse split and whether the stock price sustains the $1.00 minimum bid for the required 10 consecutive trading days to avoid delisting.
- Enquantum Milestones: Monitor the achievement of milestones required to fund the remaining ~$1.6 million commitment to Enquantum and the potential for future impairment charges.
- LGG and Innervate Progress: Track the deployment of capital into LifeSci Global Group and the development status of Innervate's radiopharmaceutical candidates, noting the high risk of loss in early-stage life sciences.
- Liquidity Runway: Assess the sufficiency of the $3.2 million cash balance against operating losses and upcoming debt maturities, particularly given the speculative nature of new ventures.
- Customer Concentration: Note that Priority Health accounted for 53% of revenue in Q1 2026; verify the stability of this relationship.